How Africa, Asia could benefit from Ticagrelor’s WHO listing
Anglo-Swedish multinational pharmaceutical and biotechnology company, AstraZeneca Plc, has recently applied to World Health Organization for the inclusion of Ticagrelor.
April 19, 2023
by SHEM OIRERE
Clinical Decision Support May Cut Cardiovascular Disease Risk
Use of clinical decision support systems (CDSSs) is associated with improvements in reversible risk for cardiovascular disease.
February 10, 2022
by drugs.com
Specialist-Led Model of Care Can Improve CVD Prevention in Psoriasis
Dermatologists and patients with psoriatic disease have a positive view of a specialist-led model of care to improve cardiovascular...
January 19, 2022
by drugs.com
USPSTF: Individualize Counseling for Primary Prevention of CVD
The U.S. Preventive Services Task Force (USPSTF) recommends that physicians individualize the decision to refer adults without...
January 18, 2022
by drugs.com
First-of-its-kind NHS gene pilot takes off
The NHS launches world-first study investigating genetic testing for common diseases.
January 18, 2022
by pharmatimes
Global Fitness Tracker Market Research Report 2021: Market Players Introduced Some Covid-19-Specific Tracking Indications to Capture the Growing Market Demand
The global fitness tracker market size is expected to reach USD 138.7 billion by 2028, registering a CAGR of 18.9%
August 19, 2021
by prnewswire
Beckman Coulter to Distribute BNP Cardiac Assay to Customers
Beckman Coulter, a global clinical diagnostics leader, announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.
July 27, 2021
by prnasia
Prior Statin Use Linked to Reduced Risk for Death in COVID-19
For patients hospitalized with COVID-19, prior use of statins, with or without antihypertensives, is associated with a reduced risk for death, according to a study published online July 15 in PLOS ONE.
July 22, 2021
by drugs
GENinCode, EVERSANA Enter Major U.S. Commercialization Pact
EVERSANA will support launch and commercialization in the U.S. market for GENinCode’s portfolio of polygenic cardiovascular disease products.
June 15, 2021
by contractpharma
Amgen announces NHS collaboration aiming to tackle high cholesterol
Amgen has announced a new partnership with two NHS organisations with the aim of tackling the ‘silent killer’ of high cholesterol across the North West Coast of England.
October 10, 2020
by pharmatimes
CVD drugs, prescription records high; cough and cold dips in June second half: Pronto Consult
The second half of June month witnessed growth momentum in the pharmaceutical products purchase, especially in the cardiovascular (CVD) therapeutic areas.
July 27, 2020
by expresspharma
Tea Drinking Linked to Reduced Risk for Atherosclerotic CVD
Habitual tea consumption is associated with a reduced risk for atherosclerotic cardiovascular disease (CVD) and all-cause mortality, according to a study published online January in the European Journal of Preventive Cardiology.
January 20, 2020
by drugs